Diabetes and Metabolism Journal

Korean Diabetes Association (대한당뇨병학회)
권호 표지
DOI QR코드

DOI QR Code

Diabetes and Osteoporosis

당뇨병과 골다공증

Oh, Ki-Won
오기원

  • Published : 20090600
⟨ Previous Next ⟩

Abstract

Increased life expectancy and increased obesity have contributed to an increasing incidence of osteoporosis and diabetes mellitus. Recent meta- nalyses and cohort studies confirm that diabetes is associated with a higher risk of fracture. Patients with type 2 diabetes exhibit increased fracture risks despite a higher bone mass, which are mainly attributable to non-skeletal risk factors. Patients with type 1 diabetes may have impaired bone formation because of absence of the anabolic effects of insulin and insulin-like growth factor I (IGF-I) system. Several clinical studies have reported adverse skeletal actions of peroxisome proliferator -activated receptor gamma (PPAR${\gamma}$) agonist in humans. Obesity regulates bone metabolism not only by increasing weight loading but also by modulating adipokines that are known to affect bone remodeling.

Keywords

References

  1. Vestergaard P: Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 18:427-44, 2007 https://doi.org/10.1007/s00198-006-0253-4
  2. Janghorbani M, Van Dam RM, Willett WC, Hu FB: Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495-505, 2007 https://doi.org/10.1093/aje/kwm106
  3. Janghorbani M, Feskanich D, Willett WC, Hu F: Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care 29:1573-8, 2006 https://doi.org/10.2337/dc06-0440
  4. Nicodemus KK, Folsom AR; Iowa Women's Health Study: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-7, 2001 https://doi.org/10.2337/diacare.24.7.1192
  5. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404-10, 2006 https://doi.org/10.1210/jc.2006-0614
  6. Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S: Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 23:1334-42, 2008 https://doi.org/10.1359/jbmr.080323
  7. Ahmed LA, Joakimsen RM, Berntsen GK, Fonnebo V, Schirmer H: Diabetes mellitus and the risk of non-vertebral fractures: the Troms${\phi}$ study. Osteoporos Int 17:495-500, 2006 https://doi.org/10.1007/s00198-005-0013-x
  8. Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J: Biphasic fracture risk in diabetes: a population-based study. Bone 40:1595-601, 2007 https://doi.org/10.1016/j.bone.2007.02.021
  9. de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA: Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-20, 2005 https://doi.org/10.1007/s00198-005-1909-1
  10. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB: Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612-7, 2005 https://doi.org/10.1001/archinte.165.14.1612
  11. Vestergaard P, Rejnmark L, Mosekilde L: Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292-9, 2005 https://doi.org/10.1007/s00125-005-1786-3
  12. Inaba M, Okuno S, Kumeda Y, Yamakawa T, Ishimura E, Nishizawa Y: Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 76:256-60, 2005 https://doi.org/10.1007/s00223-004-0094-0
  13. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ; Blue Mountains Eye Study: Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 24:1198-203, 2001 https://doi.org/10.2337/diacare.24.7.1198
  14. Lipscombe LL, Jamal SA, Booth GL, Hawker GA: The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 30:835-41, 2007 https://doi.org/10.2337/dc06-1851
  15. Wallace C, Reiber GE, LeMaster J, Smith DG, Sullivan K, Hayes S, Vath C: Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer. Diabetes Care 25:1983-6, 2002 https://doi.org/10.2337/diacare.25.11.1983
  16. Patel S, Hyer S, Tweed K, Kerry S, Allan K, Rodin A, Barron J: Risk factors for fractures and falls in older women with type 2 diabetes mellitus. Calcif Tissue Int 82:87-91, 2008 https://doi.org/10.1007/s00223-007-9082-5
  17. Goodman WG, Hori MT: Diminished bone formation in experimental diabetes. Relationship to osteoid maturation and mineralization. Diabetes 33:825-31, 1984 https://doi.org/10.2337/diabetes.33.9.825
  18. Cornish J, Callon KE, Reid IR: Insulin increases histomorphometric indices of bone formation In vivo. Calcif Tissue Int 59:492-5, 1996
  19. Thrailkill KM, Liu L, Wahl EC, Bunn RC, Perrien DS, Cockrell GE, Skinner RA, Hogue WR, Carver AA, Fowlkes JL, Aronson J, Lumpkin CK Jr: Bone formation is impaired in a model of type 1 diabetes. Diabetes 54:2875-81, 2005 https://doi.org/10.2337/diabetes.54.10.2875
  20. Stolk RP, Van Daele PL, Pols HA, Burger H, Hofman A, Birkenhäger JC, Lamberts SW, Grobbee DE: Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. Bone 18:545-9, 1996 https://doi.org/10.1016/8756-3282(96)00079-8
  21. Akune T, Ogata N, Hoshi K, Kubota N, Terauchi Y, Tobe K, Takagi H, Azuma Y, Kadowaki T, Nakamura K, Kawaguchi H: Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 159:147-56, 2002 https://doi.org/10.1083/jcb.200204046
  22. Maor G, Karnieli E: The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor. Endocrinology 140:1841-51, 1999 https://doi.org/10.1210/en.140.4.1841
  23. Campos Pastor MM, Lopez-Ibarra PJ, Escobar -Jimenez F, Serrano Pardo MD, García-Cervigon AG: Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 11:455-9, 2000 https://doi.org/10.1007/s001980070114
  24. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427 -43, 2006 https://doi.org/10.1056/NEJMoa066224
  25. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group: Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31:845-51, 2008 https://doi.org/10.2337/dc07-2270
  26. Meymeh RH, Wooltorton E: Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 177:723-4, 2007 https://doi.org/10.1503/cmaj.071177
  27. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR: Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820-5, 2008 https://doi.org/10.1001/archinte.168.8.820
  28. Loke YK, Singh S, Furberg CD: Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180:32-9, 2009 https://doi.org/10.1503/cmaj.080486
  29. Yaturu S, Bryant B, Jain SK: Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30:1574-6, 2007 https://doi.org/10.2337/dc06-2606
  30. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR: The peroxisome proliferator -activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-10, 2007 https://doi.org/10.1210/jc.2006-2646
  31. Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N, Guvener Demirag N: Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92:3523-30, 2007 https://doi.org/10.1210/jc.2007-0431
  32. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR: Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-54, 2006 https://doi.org/10.1210/jc.2005-2226
  33. Mascitelli L, Pezzetta F: Type 2 diabetes and fracture risk. Lancet 368:732, 2006 https://doi.org/10.1016/S0140-6736(06)69281-7
  34. Grey A: Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19:129-37, 2008 https://doi.org/10.1007/s00198-007-0477-y
  35. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B: Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669-80, 2007 https://doi.org/10.1210/en.2006-1587
  36. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC: Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203-16, 2004 https://doi.org/10.1677/joe.1.05723
  37. Wan Y, Chong LW, Evans RM: PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 13:1496-503, 2007 https://doi.org/10.1038/nm1672
  38. Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW: The effects of C161$\rightarrow$T polymorphisms in exon 6 of peroxisome proliferator -activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol 192:1087-93, 2005 https://doi.org/10.1016/j.ajog.2004.09.033
  39. Rhee EJ, Oh KW, Yun EJ, Jung CH, Park CY, Lee WY, Oh ES, Baek KH, Kang MI, Park SW, Kim SW: The association of Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma gene with serum osteoprotegerin levels in healthy Korean women. Exp Mol Med 39:696-704, 2007 https://doi.org/10.1038/emm.2007.76
  40. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ: Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148:903-11, 2007 https://doi.org/10.1210/en.2006-1121
  41. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA: Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res 20:994-1001, 2005 https://doi.org/10.1359/JBMR.050103
  42. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197-207, 2000 https://doi.org/10.1016/S0092-8674(00)81558-5
  43. Karsenty G: Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 4:341-8, 2006 https://doi.org/10.1016/j.cmet.2006.10.008
  44. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC: Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257:88-91, 1992 https://doi.org/10.1126/science.1621100
  45. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, Pfeilschifter J: Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 86:2032-42, 2001 https://doi.org/10.1210/jc.86.5.2032
  46. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516-8, 1986 https://doi.org/10.1038/319516a0
  47. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T: Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191:275-86, 2000 https://doi.org/10.1084/jem.191.2.275
  48. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, Terauchi Y, Kadowaki T, Takeuchi Y, Fukumoto S, Ikeda T, Hoshi K, Chung UI, Nakamura K, Kawaguchi H: Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 99:196-208, 2006 https://doi.org/10.1002/jcb.20890
  49. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY: Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21:1648-56, 2006 https://doi.org/10.1359/jbmr.060707
  50. Yamaguchi N, Kukita T, Li YJ, Kamio N, Fukumoto S, Nonaka K, Ninomiya Y, Hanazawa S, Yamashita Y: Adiponectin inhibits induction of TNF-alpha/RANKL -stimulated NFATc1 via the AMPK signaling. FEBS Lett 582:451-6, 2008 https://doi.org/10.1016/j.febslet.2007.12.037
  51. Lee WY, Rhee EJ, Oh KW, Kim SY, Jung CH, Yun EJ, Baek KH, Kang MI, Kim SW: Identification of adiponectin and its receptors in human osteoblast-like cells and association of T45G polymorphism in exon 2 of adiponectin gene with lumbar spine bone mineral density in Korean women. Clin Endocrinol (Oxf) 65:631-7, 2006 https://doi.org/10.1111/j.1365-2265.2006.02641.x
  52. Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW: Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 33:646-51, 2003 https://doi.org/10.1016/S8756-3282(03)00237-0
  53. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD: Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 92:1517-23, 2007 https://doi.org/10.1210/jc.2006-2097
  54. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T: Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 160:265-73, 2009 https://doi.org/10.1530/EJE-08-0642
  55. Thommesen L, Stunes AK, Monjo M, Grøsvik K, Tamburstuen MV, Kjøbli E, Lyngstadaas SP, Reseland JE, Syversen U: Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 99:824-34, 2006 https://doi.org/10.1002/jcb.20915
  56. Oh KW, Lee WY, Rhee EJ, Baek KH, Yoon KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, Yoo HJ, Park SW: The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 63:131-8, 2005 https://doi.org/10.1111/j.1365-2265.2005.02312.x
  57. Pistilli EE, Gordish-Dressman H, Seip RL, Devaney JM, Thompson PD, Price TB, Angelopoulos TJ, Clarkson PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Hoffman EP, Gordon PM: Resistin polymorphisms are associated with muscle, bone, and fat phenotypes in white men and women. Obesity 15:392-402, 2007 https://doi.org/10.1038/oby.2007.543
  58. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-30, 2005 https://doi.org/10.1126/science.1097243
  59. Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, Zhou HD, Wu XP, Liao EY: Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80:201-10, 2007 https://doi.org/10.1007/s00223-006-0155-7

Cited by

  1. 남성의 골밀도 영향요인 vol.18, pp.1, 2009, https://doi.org/10.5953/jmjh.2011.18.1.005
  2. 갑상선기능이 정상인 성인에서 골다공증과 갑상선호르몬의 관련성 vol.16, pp.2, 2009, https://doi.org/10.5762/kais.2015.16.2.1137
  3. Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice vol.38, pp.6, 2009, https://doi.org/10.3892/ijmm.2016.2794
  4. 광주 소재 한 종합병원을 방문한 성인에서 혈중 Osteocalcin과 HbA1c의 상관관계 vol.50, pp.3, 2009, https://doi.org/10.15324/kjcls.2018.50.3.313